PE20142040A1 - Derivados de 6,7-dihidro-5h-benzo[7]anuleno, procesos para su preparacion, productos farmaceuticos que comprenden a los mismos y su uso en la preparacion de medicamentos - Google Patents

Derivados de 6,7-dihidro-5h-benzo[7]anuleno, procesos para su preparacion, productos farmaceuticos que comprenden a los mismos y su uso en la preparacion de medicamentos

Info

Publication number
PE20142040A1
PE20142040A1 PE2014000925A PE2014000925A PE20142040A1 PE 20142040 A1 PE20142040 A1 PE 20142040A1 PE 2014000925 A PE2014000925 A PE 2014000925A PE 2014000925 A PE2014000925 A PE 2014000925A PE 20142040 A1 PE20142040 A1 PE 20142040A1
Authority
PE
Peru
Prior art keywords
preparation
benzo
anuleno
dihidro
medicines
Prior art date
Application number
PE2014000925A
Other languages
English (en)
Inventor
Tim Wintermantel
Carsten Moeller
Ulrich Bothe
Reinhard Nubbemeyer
Ludwig Zorn
Laak Antonius Ter
Rolf Bohlmann
Lars Wortmann
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47294898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20142040A1 publication Critical patent/PE20142040A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA(I) EN DONDE R1, R2, R3 Y R4 EN FORMA INDEPENDIENTE SON H, HIDROXI, ALCOXI, ENTRE OTROS; R5, R6 Y R7 EN FORMA INDEPENDIENTE SON H, FLUOR, CLORO, ENTRE OTROS; X ES H, ALQUILO, CICLOALQUILO, ENTRE OTROS; Y ES C1-C4-ALQUILO PERFLUORADO, ENTRE OTROS; m ES 4-7; n ES 2-7; p ES 0-2; q ES 1-4, SON COMPUESTOS PREFERIDOS 9-[5-(METIL{3-[(4,4,5,5,5-PENTAFLUOROPENTIL)SULFANIL]PROPIL}AMINO)PENTIL]-8-FENIL-6,7-DIHIDRO-5H-BENZO[7]ANULEN-3-OL, 9-[5-(METIL{3-[(RS)-(4,4,5,5,5-PENTAFLUOROPENTIL)SULFINIL]PROPIL}AMINO)PENTIL]-8-FENIL-6,7-DIHIDRO-5H-BENZO[7]ANULEN-3-OL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, QUE ES UTIL EN EL TRATAMIENTO DE OSTEOPOROSIS, ENDOMETRIOSIS, ENTRE OTROS.
PE2014000925A 2011-12-08 2012-12-04 Derivados de 6,7-dihidro-5h-benzo[7]anuleno, procesos para su preparacion, productos farmaceuticos que comprenden a los mismos y su uso en la preparacion de medicamentos PE20142040A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011087987A DE102011087987A1 (de) 2011-12-08 2011-12-08 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Publications (1)

Publication Number Publication Date
PE20142040A1 true PE20142040A1 (es) 2014-12-31

Family

ID=47294898

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000925A PE20142040A1 (es) 2011-12-08 2012-12-04 Derivados de 6,7-dihidro-5h-benzo[7]anuleno, procesos para su preparacion, productos farmaceuticos que comprenden a los mismos y su uso en la preparacion de medicamentos

Country Status (27)

Country Link
US (1) US20150080438A1 (es)
EP (1) EP2788321A1 (es)
JP (1) JP2015500814A (es)
KR (1) KR20140107371A (es)
CN (1) CN104185622A (es)
AP (1) AP2014007736A0 (es)
AU (1) AU2012347314A1 (es)
BR (1) BR112014013710A8 (es)
CA (1) CA2858265A1 (es)
CL (1) CL2014001513A1 (es)
CO (1) CO6970608A2 (es)
CR (1) CR20140269A (es)
CU (1) CU20140064A7 (es)
DE (1) DE102011087987A1 (es)
DO (1) DOP2014000124A (es)
EA (1) EA201491096A1 (es)
EC (1) ECSP14004206A (es)
GT (1) GT201400109A (es)
HK (1) HK1204320A1 (es)
IL (1) IL232771A0 (es)
MA (1) MA35728B1 (es)
MX (1) MX2014006910A (es)
PE (1) PE20142040A1 (es)
PH (1) PH12014501292A1 (es)
SG (1) SG11201402639WA (es)
TN (1) TN2014000247A1 (es)
WO (1) WO2013083568A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015028409A1 (de) * 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
DK3386500T3 (da) 2015-12-09 2022-12-12 Univ Illinois Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer
PT3416962T (pt) * 2016-02-15 2021-07-23 Sanofi Sa Derivados de 6,7-di-hidro-5h-benzo[7]anuleno como moduladores do recetor de estrogénio
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
JP6946430B2 (ja) 2016-11-17 2021-10-06 サノフイＳａｎｏｆｉ 新規の置換ｎ−（３−フルオロプロピル）−ピロリジン化合物、それを製造するための方法、およびその治療的使用
CN110177554B (zh) 2017-01-06 2023-06-02 G1治疗公司 用于治疗癌症的组合疗法
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN107325028B (zh) * 2017-08-16 2019-01-18 连云港恒运药业有限公司 氟维司群侧链中间体合成方法
CN109020794A (zh) * 2018-08-27 2018-12-18 上海华堇生物技术有限责任公司 3-甲氧基肉桂醛的制备方法
CN109020795A (zh) * 2018-08-27 2018-12-18 上海华堇生物技术有限责任公司 4-甲氧基肉桂醛的制备方法
CA3111359A1 (en) 2018-09-07 2020-03-12 Sanofi Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311678D0 (en) 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4426625A1 (de) 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
DE19526146A1 (de) 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19622457A1 (de) 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19636625A1 (de) 1996-09-10 1998-03-12 Bayer Ag Verfahren zur Herstellung von alpha-D-Glucopyranosido-1,6-mannit und -sorbit aus alpha-D-Glucopyranosido-1,6-fructose
EP0944613B1 (en) 1996-12-13 2002-10-09 Chugai Seiyaku Kabushiki Kaisha Benzopyran derivatives
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
KR20000001793A (ko) 1998-06-13 2000-01-15 이경하 신규한 벤조피란 또는 티오벤조피란 유도체
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19842123C1 (de) 1998-09-05 2000-07-13 Schering Ag 11beta-Fluor-7alpha-(14,14,15,15,15-pentafluor-6- methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)- trien-3,17beta-diol als kristallines Ansolvat
WO2000055137A1 (en) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE10117441A1 (de) 2001-04-03 2002-10-10 Schering Ag 1-Indolylderivate, deren Verwendung zur Herstellung von Arzneimitteln, ein Verfahren zur Herstellung der 1-Indolylderivate sowie 1-Indolylderivate enthaltende pharmzeutische Präparate
AU2002323098A1 (en) 2001-08-11 2003-03-03 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
AU2002349354B2 (en) 2001-10-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Synthesis of oxygen-substituted benzocycloheptenes, used as valuable intermediate products for producing tissue-selective oestrogens
AP2005003247A0 (en) * 2002-09-10 2005-03-31 Pharmacia & Upjohn Co Llc Acetyl 2-hydroxy-1,3 diaminoalkanes.
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
US7825109B2 (en) * 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
FR2884251B1 (fr) * 2005-04-08 2007-07-13 Servier Lab Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
PT2114955E (pt) * 2006-12-29 2013-04-18 Rigel Pharmaceuticals Inc Triazoles substituídos com arilo bicíclico em ponte ou heteroarilo bicíclico em ponte úteis como inibidores de axl
EP2048126A1 (de) * 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
US8349838B2 (en) * 2008-07-09 2013-01-08 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
DE102010030538A1 (de) * 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
HK1204320A1 (en) 2015-11-13
US20150080438A1 (en) 2015-03-19
KR20140107371A (ko) 2014-09-04
TN2014000247A1 (en) 2015-09-30
BR112014013710A2 (pt) 2017-06-13
WO2013083568A1 (de) 2013-06-13
SG11201402639WA (en) 2014-10-30
ECSP14004206A (es) 2015-12-31
IL232771A0 (en) 2014-08-03
CR20140269A (es) 2014-08-13
AU2012347314A1 (en) 2014-06-19
MX2014006910A (es) 2014-09-08
DE102011087987A1 (de) 2013-06-13
CL2014001513A1 (es) 2014-10-24
CA2858265A1 (en) 2013-06-13
PH12014501292A1 (en) 2014-09-08
GT201400109A (es) 2015-08-14
DOP2014000124A (es) 2014-07-31
CU20140064A7 (es) 2014-12-26
CN104185622A (zh) 2014-12-03
AP2014007736A0 (en) 2014-07-31
JP2015500814A (ja) 2015-01-08
CO6970608A2 (es) 2014-06-13
EP2788321A1 (de) 2014-10-15
EA201491096A1 (ru) 2015-03-31
BR112014013710A8 (pt) 2017-06-13
MA35728B1 (fr) 2014-12-01

Similar Documents

Publication Publication Date Title
PE20142040A1 (es) Derivados de 6,7-dihidro-5h-benzo[7]anuleno, procesos para su preparacion, productos farmaceuticos que comprenden a los mismos y su uso en la preparacion de medicamentos
PE20190973A1 (es) Compuestos de tetrahidropirazolopirimidina
DOP2013000181A (es) Moduladores del receptor de glucagon
UY35288A (es) Piridonamidas como moduladores de canales de sodio
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
EA201490569A1 (ru) Полиморфная форма гидрохлорида придопидина
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
GT201300254A (es) Triazolopiridinas
CO6351777A2 (es) Compuestos de tetraciclina sustituidod con fluor en c7
EA201591499A1 (ru) Замещенные бисфенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
EA201391524A1 (ru) Производные гликозида и их применение
CU20190029A7 (es) Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos
MA38854A1 (fr) Dérivés amides utilisés en tant qu&#39;antagonistes des récepteurs de l&#39;acide lysophosphatidique
EA201490573A1 (ru) Соединение бензотиазолона
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
PE20171736A1 (es) Derivados de 3-(4&#39;-sustituido)-bencil-eter de pregnenolona

Legal Events

Date Code Title Description
FD Application declared void or lapsed